Opko Health Inc (OPK) 9.61 $OPK Transition (TTHI) Stock

New Post Public Reply Private Reply Replies (0) Message Board

Jul 14, 2016 at 2:14 AM

Opko Health Inc (OPK) 9.61 $OPK

Transition (TTHI) Stock Up on News of Acquisition by Opko
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 7:59AM CDT
Transition (TTHI) signed a definitive agreement under which it will be acquired by Opko (OPK) in an all-stock transaction worth $60 million.
OPK: 9.61 (-0.30), PFE: 36.31 (+0.07), TTHI: 1.54 (-0.01), BMY: 76.58 (+0.38)

OPKO Health to Acquire Transition Therapeutics
BusinessWire - Thu Jun 30, 1:00AM CDT
--OPKO to gain potential first-to-market GLP-1/Glucagon dual agonist for type 2 diabetes and obesity and phase 2 drug candidate for the treatment of androgen deficiency
TTH.TO: 2.03 (unch), OPK: 9.61 (-0.30), TTHI: 1.54 (-0.01)

Opko Health (OPK) Catches Eye: Stock Adds 5.6% in Session
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:15AM CDT
Opko Health, Inc. (OPK) shares rose almost 6% in the last trading session.
OPK: 9.61 (-0.30), CRY: 12.35 (+0.15)

Here's Why Opko Health (OPK) Stock Is Gaining Today
Ryan McQueeney - Zacks Investment Research - Tue Jun 21, 11:31AM CDT
Shares of Opko Health (OPK) are up nearly 5.5% in morning trading Tuesday following the news that the FDA has approved its new treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease.
OPK: 9.61 (-0.30)

Company News for June 21, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:10AM CDT
Companies in the News are: MRO,OPK,DIS,LC
LC: 4.25 (+0.15), OPK: 9.61 (-0.30), DIS: 99.88 (-0.32), MRO: 15.29 (-0.31)

VBI Vaccines Announces Closing of $13.6 Million Private Placement
Marketwire Canada - Tue Jun 21, 7:30AM CDT
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Jun 21, 2016) - VBI Vaccines (NASDAQ:VBIV)(TSX:VBV) ("VBI"

, today announced the closing of an equity private placement financing led by OPKO Health (NYSE:OPK) and Perceptive Advisors, with participation by ARCH Venture Partners. In accordance with Toronto Stock Exchange (TSX) regulations, aggregate participation by certain current investors was limited to 10% of the issued and outstanding common shares in any given 6-month period. As a result, these current investors in VBI participated to their maximum possible allocation.
OPK: 9.61 (-0.30), VBIV: 3.83 (-0.03), VBV.TO: 5.01 (+0.01)

FDA Approves New Drug Application for RAYALDEE(R) to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease
BusinessWire - Tue Jun 21, 1:00AM CDT
--There are Approximately 9 Million Patients in the U.S. with SHPT, Stage 3 or 4 CKD and Vitamin D Insufficiency; Large Potential U.S. Market
OPK: 9.61 (-0.30)

Opko Health Inc Enters Oversold Territory (OPK)
MarketNewsVideo.com - Tue Jun 14, 11:09AM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
OPK: 9.61 (-0.30)

OPKO Health Announces Move to NASDAQ Stock Market
BusinessWire - Mon Jun 13, 8:10AM CDT
OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company"

announces that it will move its stock exchange listing to The NASDAQ Stock Market from The New York Stock Exchange (the "NYSE"

. The Company expects its common stock will begin trading on the NASDAQ Global Select Market ("NASDAQ"

on June 24, 2016, and its shares will continue to trade under the ticker symbol "OPK."
OPK: 9.61 (-0.30)

Covered Call Alerts For Gilead Sciences, Western Digital, Costco, Opko Health and Ulta Salon Cosmetics & Fragrance Inc. Released By InvestorsObserver
PR Newswire - Wed Jun 08, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, WDC, COST, OPK and ULTA.
OPK: 9.61 (-0.30), GILD: 85.75 (-0.88), COST: 166.78 (+0.50), ULTA: 250.13 (-3.12), WDC: 52.01 (+0.17)

OPKO to Discuss Draft Coverage Determinations for 4Kscore(R) Test at 2016 Jefferies Healthcare Conference
BusinessWire - Tue Jun 07, 3:05PM CDT
OPKO Health, Inc. (NYSE: OPK) today announced that senior management will discuss recent draft local coverage determinations by certain Medicare Administrative Contractors for OPKO's 4Kscore(R) test at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT). OPKO previously announced that Novitas Solutions issued a positive draft local coverage determination proposing to establish reimbursement coverage for patients with PSA levels > 3 ng/mL who have not yet had a biopsy, or patients with a PSA level of > 3 ng/mL who have had at least one prior negative biopsy and are considered to be at higher risk. The draft coverage determination was subsequently retired by Novitas due to a potential conflict with another Medicare Administrative Contractor. Palmetto GBA had issued a draft non-coverage determination on May 27th for the 4Kscore test.
OPK: 9.61 (-0.30)

Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 61.57 (-0.58), ACAD: 32.92 (-1.76), OPK: 9.61 (-0.30), CLDX: 4.42 (-0.19)

OPKO Health to Present at the 2016 Jefferies Healthcare Conference
BusinessWire - Thu Jun 02, 7:47AM CDT
OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT).
OPK: 9.61 (-0.30)

OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination for 4Kscore(R) Test
BusinessWire - Fri May 27, 7:30AM CDT
OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company"

announces that Novitas Solutions has issued a draft local coverage determination for the 4Kscore(R) Test, the only blood test that accurately identifies an individual patient's risk for high-grade, aggressive prostate cancer. Novitas Solutions is a Medicare Administrative Contractor (MAC) for Medicare jurisdictions L and H, with responsibility for nearly 10 million Medicare beneficiaries in New Jersey, Pennsylvania, Maryland, the District of Columbia and Texas, among other geographies.
OPK: 9.61 (-0.30)

Global Vitamin D Deficiency Disorders Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Merck, OPKO Health, DSM Biologics Holdings - Research and Markets
BusinessWire - Fri May 27, 6:57AM CDT
Research and Markets has announced the addition of the "Vitamin D Deficiency Disorders Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
OPK: 9.61 (-0.30), MRK: 59.55 (-0.05)

OPKO Health, Inc. - Product Pipeline Review - 2016 - Research and Markets
BusinessWire - Thu May 26, 4:36PM CDT
Research and Markets has announced the addition of the "OPKO Health, Inc. - Product Pipeline Review - 2016" company profile to their offering.
OPK: 9.61 (-0.30)

Under Armour trade offers a 19% return in 52 days, or find similar option trades on Opko Health, Herbalife, Costco, and Microsoft
PR Newswire - Wed May 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for UA, OPK, HLF, COST and MSFT.
UA: 41.51 (-0.29), HLF: 59.41 (-2.46), OPK: 9.61 (-0.30), COST: 166.78 (+0.50), MSFT: 53.51 (+0.30)

Cocrystal Pharma to Present at Jefferies 2016 Healthcare Conference
Marketwired - Wed May 25, 7:01AM CDT
Cocrystal CEO & CMO to Present Thursday, June 9, 2016, 8:30 AM ET in NYC
OPK: 9.61 (-0.30)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Cancer Memoir Shows Healing Beyond Medicine

Confronting the Unfathomable Out of the North Carolina mountains comes a story that defies expectations—a pastor and farmer named Mark Heisey, who faced the no-holds-barred trials of stage IV-B lymphoma. Now, I'll shoot you straight: this isn't your run-of-the-mill self-help guide or a clinical breakdown of battling cancer. His new memoir dives into the personal and...

Nomada Fund Launches: A Game-Changer in New Media

Changing the Investment Game In a world where tech isn't the only kingmaker, distribution is the new play. Welcome the Nomada Fund, a fresh face on the investment scene that's swapping cash for exposure. Forget the traditional media-for-equity model that only old-timers still drool over—these guys are taking it up a notch with their new Distribution for Equity approach,...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

TomoIQ Unveils Money Finder at Money20/20 Event

Breaking Down Financial Barriers with AI In the hustle of Money20/20 USA in Las Vegas, TomoIQ dropped a financial bombshell with their latest tool, Money Finder. This isn't just another app in the sea of fintech solutions. Nope, this one promises to cut through the complexities that most folks face when trying to get their financial house in order. An AI Buddy for...

Chicago Scenic Studios’ Equipment Up for Grabs in Auction

A Peek into the Sale: What's on the Block? Get that coffee brewing and settle in, because we've got to unpack some interesting stuff happening with Chicago Scenic Studios. This isn't just any Craigslist decampment—Integra Asset Solutions is rolling out an online auction come October 27 that’ll have equipment-savvy investors’ ears perking up like they just snagged a...

Alpha Rising Joins RFP: A Strong AI-Fueled Expansion

The Shift: From LPL to AI-Driven Innovation Hold onto your hats, because Alpha Rising Wealth Management has taken a significant leap from the traditional ship of LPL Financial to the cutting-edge shores of Rothschild Financial Partners (RFP). It's a move that's painting the walls in Scottsdale, Arizona with $250 million in client assets, all set to benefit from a modern,...

Dickinson Brands Celebrates Witch Hazel Legacy with Event

Witch Hazel's Timeless Appeal You don’t get to celebrate over one and a half centuries of a product without doing something right. Dickinson Brands Inc. is throwing a bash worth noticing as they mark the sixth annual National Witch Hazel Day on October 21st. It’s a head-nod to the versatile witch hazel, a product that’s been part of New England's heritage since the...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

2GenPen & LordCap Team Up: Game-Changer in ABS?

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...